Author

Jonathan Sumner

AstraZeneca (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:CRISPR screen· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Mike A. Firth· 2 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anja van Brabant SmithiD· 1 shared Bastian SchiffthaleriD· 1 shared Ben TayloriD· 1 shared Björn Magnusson· 1 shared Bronwyn C. Joubert· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Mike A. Firth

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An aptamer-mediated base editing platform for simultaneous knock-in and multiple gene knockout for allogeneic CAR-T cells generation

Immacolata Porreca, Robert A. Blassberg, Jennifer A. Harbottle, Bronwyn C. Joubert, Olga Mielczarek, Jesse Stombaugh, Kevin Hemphill, Jonathan Sumner, Deividas Pazeraitis, Julia Liz Touza, Margherita Francescatto, Mike A. Firth, Tommaso Selmi, Juan Carlos Collantes, Žaklina Strezoska, , John J. Lambourne

This paper introduces a base editing platform for simultaneous gene knockout and transgene integration in T cells, showing higher efficiency and reduced chromosomal translocations compared to CRISPR-Cas9.

Molecular Therapy · Jun 26, 2024Peer-reviewedMolecular Biology

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike A. Firth, Johan Brengdahl, Susanna Engberg, Marie K. Schwinn, Michael R. Slater, Anders Lundin, Pei-Pei Hsieh, Songyuan Li, Silvia Cerboni, Jonathan Sumner, Burcu Bestas, Bastian Schiffthaler, Björn Magnusson, , Marcello Maresca

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

Nature Communications · Aug 14, 2023Peer-reviewedMolecular Biology